Retatrutide, developed by Soma, represents a exciting breakthrough in metabolic management . This dual-action drug combines incretin receptor properties with gut-derived pathway stimulation , showing substantial results in patient studies for weight loss . Experts believe the drug may provide a alternative pathway for patients struggling with exces